RoyBTishlerMD
Radiation Oncology • Boston, MAAssociate Professor of Radiation Oncology, Dana-Farber Cancer Institute
Dr. Tishler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
# ASB1-L2
Boston, MA 02115Phone+1 617-632-3591Fax+1 617-632-4247
Education & Training
Brigham and Women's Hospital/Joint Center for Radiation TherapyResidency, Radiation Oncology, 1990 - 1993
New York Presbyterian Hospital (Columbia Campus)Residency, Radiation Oncology, 1988 - 1990- New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1987 - 1988
Johns Hopkins University School of MedicineClass of 1987
Certifications & Licensure
NY State Medical License 1988 - Present
MA State Medical License 1993 - 2025
CT State Medical License 2022 - 2024
ME State Medical License 2020 - 2021- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Super Doctor SuperDoctors.com
Clinical Trials
- Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2000 Jul 14
- Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck Start of enrollment: 2007 Nov 01
Publications & Presentations
PubMed
- 1148 citationsCisplatin and fluorouracil alone or with docetaxel in head and neck cancer.Marshall R. Posner, Diane Hershock, Cesar R. Blajman, Elizabeth Mickiewicz, Eric Winquist
The New England Journal of Medicine. 2007-10-25 - 25 citationsCost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus Proton Therapy for Oropharyngeal Squamous Cell Carcinoma.David J. Sher, Roy B. Tishler, Nhat-Long Lam Pham, Rinaa S. Punglia
International Journal of Radiation Oncology, Biology, Physics. 2018-07-15 - 195 citationsNeoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.Jonathan D. Schoenfeld, Glenn J. Hanna, Vickie Y. Jo, Bhupendra Rawal, Yu-Hui Chen
JAMA Oncology. 2020-10-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
